Delcath Systems, Inc. (DCTH)

Over the past six months, Delcath Systems, Inc.'s stock price has been influenced by several events. In October 2025, the stock fell due to lower-than-expected revenue and lowered guidance, attributed to Medicaid discounts and summer seasonality. In November 2025, a $25 million stock buyback program was initiated. December 2025 saw the publication of subgroup analyses from the Phase 3 FOCUS study. In February 2026, the company reported a net income of $2.7 million for the full year 2025. In March 2026, full CHOPIN clinical trial results were published in The Lancet Oncology, highlighting improved outcomes when combining HEPZATO KIT with immunotherapy drugs, but consensus EPS estimates were downgraded. In April 2026, CHEMOSAT was included in the ESMO–EURACAN Clinical Practice Guidelines, and an analyst upgraded the stock. As of April 7, 2026, the stock was down 4.26% year-to-date.

Delcath Systems, Inc. has experienced demand seasonality, with "summer seasonality" impacting new patient starts and revenue, contributing to the company lowering its full-year 2025 revenue guidance.

Delcath Systems, Inc. is an interventional oncology company specializing in liver-directed cancer therapies, including the HEPZATO KIT and CHEMOSAT Hepatic Delivery System for Melphalan. These products administer high-dose chemotherapy directly to the liver, minimizing systemic exposure. The HEPZATO KIT is regulated as a drug in the US, while CHEMOSAT is approved as a medical device in Europe. The company's clinical development program includes the FOCUS clinical trial for metastatic hepatic dominant uveal melanoma.

Delcath Systems, Inc. conducts its business operations in the United States and Europe.

Delcath Systems, Inc.'s brand reputation has been positively influenced by clinical advancements and recognition within the medical community. Positive results from the CHOPIN clinical trial and the inclusion of CHEMOSAT in the ESMO–EURACAN Clinical Practice Guidelines have solidified the company's standing. Publications supporting the early use of liver-directed therapy have also contributed positively. A stock price drop in October 2025 was related to financial performance rather than the brand's medical reputation.

Delcath Systems, Inc. has a diverse ownership structure. Institutional shareholders hold approximately 49.29% of the company's stock, while insiders own about 70.11%, and retail investors hold 0.00%. Other sources indicate institutional ownership around 21.80% to 37.52%, insider ownership around 31.47%, and public companies and individual investors holding approximately 8.55% to 31.01%. Major institutional owners include Rosalind Advisors, Inc., BlackRock, Inc., Vanguard Group Inc, Geode Capital Management, Llc, State Street Corp, Goldman Sachs Group Inc, Divisadero Street Capital Management, LP, Propel Bio Management, LLC, Ikarian Capital, LLC, and ExodusPoint Capital Management, LP. Rosalind Advisors Inc. is noted as the largest individual shareholder, owning 9.19 million shares, representing 26.45% of the company. Steven A. J. Salamon and Gil Aharon are also significant individual owners.